Biotech

All Articles

Biogen, UCB record phase 3 lupus win after falling short earlier test

.Biogen and also UCB's bank on developing right into phase 3 astride a failed research seeks to have...

Aptadir really hopes new RNA inhibitors can easily turn around tricky cancers

.Italian biotech Aptadir Therapeutics has actually launched along with the guarantee that its own pi...

Wave surfs DMD effectiveness to regulators' doors, sending stockpile

.Surge Life Sciences has satisfied its objective in a Duchenne muscle dystrophy (DMD) research, posi...

Sanofi tweezes brand new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma crease, taking up th...

Achilles splashes cell treatment plan, bandages for cutbacks after missing out on 'business viability' goals

.Achilles Therapeutics has actually shreded its own technique. The English biotech is actually quiti...

Aligos trumpets phase 2 MASH win, lowering liver body fat approximately 46%

.Aligos Rehabs is declaring a midstage succeed in metabolic-dysfunction associated steatohepatitis (...

Basilea ratings $268M BARDA funding for antifungals, antibiotics

.Basilea Pharmaceutica's work building new antifungals has gotten a notable improvement from the U.S...

Capricor markets Europe liberties to late-stage DMD therapy for $35M

.Possessing presently scooped up the united state legal rights to Capricor Therapeutics' late-stage ...

FDA junks adcomm for Applied's unusual condition medication

.After pushing the selection date for Applied Rehabs' metabolic problem medication govorestat, the F...

Novo inks $600M NanoVation deal to examine hereditary drugs ex-liver

.Novo Nordisk is continuing its press in to genetic medicines, accepting pay NanoVation Therapeutics...